



# Evusheld® No Longer Authorized to Prevent COVID-19

---

February 14, 2023

## What Pharmacy Providers and Prescribers Need to Know

Effective for dates of service (DOS) on or after January 26, 2023, the Department of Health Care Services (DHCS) will no longer reimburse Evusheld® (tixagevimab co-packaged with cilgavimab) as a pharmacy benefit. Evusheld is a monoclonal antibody for the pre-exposure prophylaxis of COVID-19 in certain adults as well as pediatric individuals 12 years of age and older weighing at least 40 kg. On January 26, 2023, the [U.S. Food and Drug Administration \(FDA\) announced](#) that Evusheld is no longer authorized for use in the U.S. until further notice by the FDA.

Data shows that Evusheld is [unlikely to be active](#) against certain SARS-CoV-2 variants. According to the most recent Centers for Disease Control and Prevention (CDC) [COVID Data Tracker](#), these variants are projected to be responsible for more than 90 percent of current infections in the U.S. This means that Evusheld is not expected to provide protection against developing COVID-19 if exposed to those variants. Therefore, pharmacy providers must not submit claims for Evusheld for DOS on or after January 26, 2023, as they will be denied.

There are [several treatments](#) – Paxlovid™ (nirmatrelvir co-packaged with ritonavir), Veklury® (remdesivir), and Lagevrio™ (molnupiravir) – that are expected to work against currently circulating variants and are authorized or approved to treat certain patients with mild-to-moderate COVID-19 who are at a high risk for progression to a severe case, including hospitalization or death. Health care providers should assess whether these treatments are right for their patients.

## What Pharmacy Providers and Prescribers Need to Do

- Refer to [Variant Proportions](#) in the U.S. on the CDC website for general information.

- Refer to the [California COVID-19 Response](#) website for California-specific information.

## Contact Information

You can call the Medi-Cal Rx Customer Service Center (CSC) at 1-800-977-2273, which is available 24 hours a day, 7 days a week, 365 days per year.

For other questions, email Medi-Cal Rx Education & Outreach at [MediCalRxEducationOutreach@magellanhealth.com](mailto:MediCalRxEducationOutreach@magellanhealth.com).

ARCHIVED